Evidence map›Paper›PMID 27771773›Full record

ArticleInternational journal of colorectal disease2017

Case-control study of candidate gene methylation and adenomatous polyp formation.

M Alexander, J B Burch, S E Steck, C-F Chen, T G Hurley, P Cavicchia, N Shivappa, J Guess, H Zhang, S D Youngstedt and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of colorectal disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

M AlexanderSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.ORCID http://orcid.org/0000-0003-4261-6543
J B BurchSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA. burch@mailbox.sc.edu.
S E SteckSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.
C-F ChenCenter for Molecular Studies, Greenwood Genetic Center, Greenwood, SC, USA.
T G HurleySouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.
P CavicchiaSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.
N ShivappaSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.
J GuessSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.
H ZhangDivision of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, TN, USA.
S D YoungstedtCollege of Nursing and Health Innovation, College of Health Solutions, Arizona State University and Phoenix VA Health Care System, Phoenix, AZ, USA.
K E CreekDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA.
S LloydSouth Carolina Medical Endoscopy Center, and Department of Family Medicine, University of South Carolina School of Medicine, Columbia, SC, USA.
K JonesCenter for Molecular Studies, Greenwood Genetic Center, Greenwood, SC, USA.
J R HébertSouth Carolina Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.

Funding

TISSUE BIOREPOSITORYP20RR017698 · NCRR · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI OUTTEN, FRANKLIN WAYNE · 2002 to 2011
$22.5M
TISSUE BIOREPOSITORY COREP30GM103336 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BERGER, FRANKLIN G. · 2013 to 2017
$5.4M
Training ProgramU54CA153461 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HEBERT, JAMES R · 2010 to 2015
$4.8M
Biomedical-Behavioral Interface: Prevention and Developmental Sciences TrainingT32GM081740 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI PRINZ, RONALD J · 2008 to 2022
$4.5M
South Carolina Cancer Disparities Community NetworksU01CA114601 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HEBERT, JAMES R · 2005 to 2010
$3.8M
Expanding Mentoring Capacity in High-Risk PopulationsK05CA136975 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HEBERT, JAMES R · 2009 to 2013
$801k
NCI NIH HHS K05 CA136975NCI NIH HHS U01 CA114601NCI NIH HHS U54 CA153461NCRR NIH HHS P20 RR017698NIGMS NIH HHS P30 GM103336NIGMS NIH HHS T32 GM081740
6 · The paper itself

Abstract

purposeColorectal cancer (CRC) is one of the most common and preventable forms of cancer but remains the second leading cause of cancer-related death. Colorectal adenomas are precursor lesions that develop in 70-90 % of CRC cases. Identification of peripheral biomarkers for adenomas would help to enhance screening efforts. This exploratory study examined the methylation status of 20 candidate markers in peripheral blood leukocytes and their association with adenoma formation.

methodsPatients recruited from a local endoscopy clinic provided informed consent and completed an interview to ascertain demographic, lifestyle, and adenoma risk factors. Cases were individuals with a histopathologically confirmed adenoma, and controls included patients with a normal colonoscopy or those with histopathological findings not requiring heightened surveillance (normal biopsy, hyperplastic polyp). Methylation-specific polymerase chain reaction was used to characterize candidate gene promoter methylation. Odds ratios (ORs) and 95 % confidence intervals (95% CIs) were calculated using unconditional multivariable logistic regression to test the hypothesis that candidate gene methylation differed between cases and controls, after adjustment for confounders.

resultsComplete data were available for 107 participants; 36 % had adenomas (men 40 %, women 31 %). Hypomethylation of the MINT1 locus (OR 5.3, 95% CI 1.0-28.2) and the PER1 (OR 2.9, 95% CI 1.1-7.7) and PER3 (OR 11.6, 95% CI 1.6-78.5) clock gene promoters was more common among adenoma cases. While specificity was moderate to high for the three markers (71-97 %), sensitivity was relatively low (18-45 %).

conclusionFollow-up of these epigenetic markers is suggested to further evaluate their utility for adenoma screening or surveillance.

Indexed as

Genetic Association StudiesAdenomatous PolypsAgedCase-Control StudiesDNA MethylationFemaleHumansMaleMiddle AgedOdds RatioPromoter Regions, GeneticAdenomatous polypCircadian rhythmColorectal cancerScreening tests

Identifiers

PMID27771773
PMCPMC5288296

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.